Intervention Protocol

You have free access to this content

Fulvestrant for hormone-sensitive metastatic breast cancer

  1. Clara I Lee1,2,
  2. Annabel Goodwin3,
  3. Orit Freedman4,
  4. Mark Clemons5,
  5. Nicholas Wilcken2,6,*

Editorial Group: Cochrane Breast Cancer Group

Published Online: 1 MAY 2014

DOI: 10.1002/14651858.CD011093

How to Cite

Lee CI, Goodwin A, Freedman O, Clemons M, Wilcken N. Fulvestrant for hormone-sensitive metastatic breast cancer (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 5. Art. No.: CD011093. DOI: 10.1002/14651858.CD011093.

Author Information

  1. 1

    Westmead Hospital, Medical Oncology, Westmead, Australia

  2. 2

    The University of Sydney, Sydney Medical School, Sydney, Australia

  3. 3

    Concord Hospital, Medical Oncology/Cancer Genetics, Concord, NSW, Australia

  4. 4

    Durham Regional Cancer Centre, Medical Oncology, Oshawa, Canada

  5. 5

    The Ottawa Hospital Cancer Centre, Division of Medical Oncology, Ottawa, Ontario, Canada

  6. 6

    Westmead and Nepean Hospitals, Medical Oncology, Westmead, NSW, Australia

*Nicholas Wilcken,

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 1 MAY 2014




  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the efficacy and safety of fulvestrant for hormone-sensitive locally advanced or metastatic breast cancer in post-menopausal women.